Abstract: The invention uses intestinal microbial flora and combinations thereof as a liver cancer biomarker and provide a method for detection, in short, the intestinal microbial flora of the invention can be used as a liver cancer biomarker and can be used as a non-invasive method for detecting or predicting liver cancer, combined with conventional blood tests, not only capable of improving the accuracy rate of detection, but also capable of increasing the willingness of patients to participate in detection to achieve the efficacies of early prevention and early treatment.

Abstract: Disclosed herein is a novel use of HSD3B1 in disease diagnosis. According to embodiments of the present disclosure, the mRNA or protein level of HSD3B1 may serve as an indicator for diagnosing hepatocellular carcinoma. Also disclosed herein are methods for treating hepatocellular carcinoma by use of HSD3B1 inhibitor.

Abstract: Disclosed herein is a novel use of HSD3B1 in disease diagnosis. According to embodiments of the present disclosure, the mRNA or protein level of HSD3B1 may serve as an indicator for diagnosing hepatocellular carcinoma. Also disclosed herein are methods for treating hepatocellular carcinoma by use of HSD3B1 inhibitor.